Evaluating a new imaging technique for brain tumors
Official title: Application of 99mTc-CNDG SPECT/CT Imaging in the Diagnosis of Brain Tumors
Run by Peking Union Medical College Hospital · NCT06362304 · Data updated 2026-11-12
This study is testing a new imaging method for brain tumors to see if it works better than the standard method currently used.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | April 20, 2024 |
| Main results expected | February 2025 |
| Study ends | April 2025 |
| Registry record updated | November 25, 2024 |
| Trial ID | NCT06362304 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a clinical diagnosis of brain tumors who can provide informed consent.
✕Probably not a fit
Patients with insulin-dependent diabetes, severe liver or kidney disease, or those undergoing current cancer treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to assess the effectiveness of 99mTc-CNDG SPECT/CT in diagnosing brain tumors by comparing its diagnostic consistency with the established 18F-FDG-PET method. Participants will undergo both imaging techniques within two weeks prior to surgery, allowing for a direct comparison against pathological diagnoses obtained from surgical or biopsy samples. The study seeks to determine the correlation between the maximum standardized uptake value (SUVmax) of 99mTc-CNDG and different tumor types.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of brain tumor diagnoses, leading to better treatment planning.
How similar studies have gone: While there have been studies comparing various imaging techniques for brain tumors, the specific use of 99mTc-CNDG in this context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with clinical diagnosis of brain tumor; * Be at least 18 years old; * The final pathological results could be obtained by surgery or biopsy; * Informed consent and the ability to be followed up; * Those who did not meet the exclusion criteria. Exclusion Criteria: * Insulin-dependent diabetes mellitus or fasting blood glucose \>7 mmol/L before 99mTc-CNDG injection; * Severe liver or kidney disease (serum creatinine level \>3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal); * Severe hypersensitivity or hypersensitivity to radiocontrast agents; * Claustrophobia (inability to undergo SPECT/CT or PET/CT scans); * Patients receiving radiotherapy and chemotherapy; * Being pregnant or breastfeeding.
Where it's running
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Zhaohui Zhu
- Email: 13611093752@163.com
- Phone: 01069154241
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ABY-029 to highlight gliomas during surgery
This will test whether tiny doses of ABY-029 help surgeons see glioma tumors better during open brain surgery in adults.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Glycogen Storage Disease and Brain Function in People Like You
This study tests whether people with glycogen storage disease perform differently on cognitive tests and show different brain imaging features compared with healthy peers.
-
FAPI PET Imaging to See Fibroblast Activity in Nonischemic Cardiomyopathy
This study tests whether a special PET/CT scan using 18F-AlF-NOTA-FAPI-04 can reveal active fibroblast activity in the hearts of adults with nonischemic cardiomyopathy to help understand disease behavior and guide care.
-
Ivonescimab with GEMOX as neoadjuvant and conversion therapy for biliary tract cancer
This study tests whether adding Ivonescimab to GEMOX can help patients with biliary tract cancer shrink tumors before surgery or enable conversion to operable disease.
-
Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer
This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.